Compare LIND & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | PHAR |
|---|---|---|
| Founded | 1979 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2011 | 2020 |
| Metric | LIND | PHAR |
|---|---|---|
| Price | $21.00 | $11.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $22.25 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 600.5K | 6.1K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.97 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.98 | $10.04 |
| Revenue Next Year | $6.98 | $2.51 |
| P/E Ratio | ★ $242.11 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $8.69 |
| 52 Week High | $22.07 | $21.34 |
| Indicator | LIND | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 61.18 | 20.60 |
| Support Level | $11.67 | $11.02 |
| Resistance Level | $21.41 | $17.70 |
| Average True Range (ATR) | 1.13 | 0.37 |
| MACD | 0.25 | -0.37 |
| Stochastic Oscillator | 75.70 | 3.49 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.